JADE CURY MARTINS ASFORA LINS
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
14 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 14
- Image-guided lymph node core needle biopsy in mycosis fungoides/Sezary syndrome: Direct comparison to surgical excision(2022) CURY-MARTINS, Jade; COUTO NETTO, Sergio Dias do; CASTRO, Stephanie Catarine Carqueijo de; SIQUEIRA, Sheila Aparecida Coelho; GIANNOTTI, Marcelo Abrantes; ZERBINI, Maria Claudia Nogueira; PEREIRA, Juliana; CULLER, Hebert; TEIXEIRA JR., Frederico Jose Ribeiro; MENEZES, Marcos Roberto de; SANCHES, Jose Antonio
- Extra-acral cutaneous sclerosing perineurioma with CD34 fingerprint pattern(2017) MACARENCO, Ricardo S.; CURY-MARTINS, JadeSclerosing perineuroma is a variant of extraneural perineurioma that, as a rule, occurs in acral sites. However, it has also been occasionally reported in non-acral regions. Recently, CD34 expression in a pattern reminiscent of the human fingerprint has been observed in a subset of perineuriomas, but this immunohistochemical finding has not been documented in non-acral sclerosing perineuriomas. We report a case of sclerosing perineurioma presenting CD34 expression in a fingerprint-like pattern on the skin of the neck (a previously unreported site for this neoplasm) of a 56-year-old man. In addition, alpha smooth-muscle actin showed a similar pattern of expression, suggesting that the cell population implicated in the remarkable immunolabeling is most probably fibroblastic/myofibroblastic. Other immunohistochemical findings included epithelial membrane antigen and claudin1positive lesional cells, and the absence of S100, glucose transporter protein 1, MUC4 and desmin.
- Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel(2020) CURY-MARTINS, Jade; ERIS, Adriana Pessoa Mendes; ABDALLA, Cristina Martinez Zugaib; SILVA, Giselle de Barros; MOURA, Veronica Paula Torel de; SANCHES, Jose AntonioWith the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences. (C) 2020 Sociedade Brasileira de Dermatologia.
- Dermoscopy of primary cutaneous B- and T-cell lymphomas and pseudolymphomas presenting as solitary nodules and tumors: a case-control study with histopathologic correlation(2019) NAVARRETE-DECHENT, Cristian; PUERTO, Constanza del; ABARZUA-ARAYA, Alvaro; MOLGO, Montserrat; GELLER, Shamir; ANDREANI, Sebastian; CURY-MARTINS, Jade; SANCHES, Jose A.; MONTOYA, Javier; GONZALEZ, Sergio; URIBE, PabloBackground Primary cutaneous lymphomas (PCLs) and pseudolymphomas presenting as single pink-red nodules/tumors are highly unspecific and include a wide differential diagnosis. Objective To describe the dermoscopic characteristics of PCL/pseudolymphoma. Methods In this retrospective, case-control study, we evaluated the dermoscopic features of patients with solitary PCL/pseudolymphoma tumors and compared them to a control group of non-lymphomatous, nonpigmented, solitary tumors (e.g., basal cell carcinoma, amelanotic melanoma, etc). Results We included 14 patients with PCL/pseudolymphomas and 35 controls. T-cell and B-cell lymphoma proportions were 28.6% (n = 4) and 71.4% (n = 10), respectively. Compared to controls, most lymphomas presented dermoscopically with orange color (71.4% vs. 14.2%, P < 0.001), follicular plugs (85% vs. 2.8%, P < 0.001), and as organized lesions (85% vs. 31.4%, P = 0.001). Coexistence of orange color and follicular plugs had an odds ratio (OR) of 2.8 (P < 0.001), highly suggestive of PCL . The kappa index for independent observers was 0.66, 0.49, 0.43 for orange background, follicular plugs, and organized lesion, respectively. Histopathologic correlation was performed in six PCL cases and showed dense diffuse and perifollicular lymphocytic infiltrate in all cases and keratin plugs in five of six cases, possibly correlating with the orange color and the follicular plugs, respectively. Conclusion Primary cutaneous lymphomas/pseudolymphomas present with characteristic dermoscopic findings irrespective of immunohistochemical subtype.
- Progression of mycosis fungoides after treatment with dupilumab: A case report(2020) MIYASHIRO, Denis; VIVARELLI, Ana Gabriela; GONCALVES, Fernanda; CURY-MARTINS, Jade; SANCHES, Jose Antonio
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital(2022) CEGLIO, William Queiroz Guimaraes Wiegandt; REBEIS, Marina Mattos; SANTANA, Marcela Ferreira; MIYASHIRO, Denis; CURY-MARTINS, Jade; SANCHES, Jose AntonioBackground: Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen. Objective: To evaluate the most common adverse events, as well as the drugs associated with their appearance and the consequences for cancer treatment. Methods: A retrospective study was carried out through the analysis of patients treated at the Clinical Dermatology Unit of a public oncologic hospital. Results: A total of 138 patients with 200 adverse events were evaluated. The most commonly identified adverse events were nail and periungual changes (20%), papulopustular eruptions (13%), acneiform eruptions (12%), hand-foot syndrome (6.5%), hand-foot skin reaction (6%), and xerosis (6%). The most frequently associated antineoplastic treatment groups were classical chemotherapy (46.2%), target therapy (32.3%), and other non-antineoplastic drugs used in neoplasia protocols (16.5%). Of the total number of patients, 17.4% had their treatment suspended or changed due to a dermatological adverse event. Study limitations: Retrospective study and analysis of patients who were referred for specialized dermatological examination only, not allowing the assessment of the actual incidence of adverse events. Conclusion: A wide variety of dermatological manifestations are secondary to antineoplastic treatment with several different drugs resulting, not rarely, in the interruption or modification of therapeutic regimens. (C) 2021 Sociedade Brasileira de Dermatologia.
- Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey(2023) QUAGLINO, Pietro; SCARISBRICK, Julia; ROCCUZZO, Gabriele; ABELDANO, Alejandra; BATTISTELLA, Maxime; MCCORMACK, Chris; COWAN, Richard; COZZIO, Antonio; CURY-MARTINS, Jade; ENZ, Paula; GESKIN, Larisa; GUENOVA, Emmanuella; KIM, Youn H.; KNOBLER, Robert; LITVINOV, Ivan V.; MIYAGAKI, Tomomitsu; MOLGO, Montserrat; NICOLAY, Jan; PAPADAVID, Evangelina; PINTER-BROWN, Lauren; VALLVERDU, Ramon Pujol; QUERFELD, Christiane; ORTIZ-ROMERO, Pablo; STADLER, Rudolf; VERMEER, Maarten H.; BAGOT, Martine; HODAK, EmmiliaBackground Consensus about the definition and classification of 'plaque' in mycosis fungoides is lacking. ObjectivesTo delineate a comprehensive view on how the 'plaque' entity is defined and managed in clinical practice; to evaluate whether the current positioning of plaques in the TNMB classification is adequate. MethodsA 12-item survey was circulated within a selected panel of 22 experts (pathologists, dermatologists, haematologists and oncologists), members of the EORTC and International Society for Cutaneous Lymphoma. The questionnaire discussed clinical and histopathological definitions of plaques and its relationship with staging and treatment. Results Total consensus and very high agreement rates were reached in 33.3% of questions, as all panellists regularly check for the presence of plaques, agree to evaluate the presence of plaques as a potential separate T class, and concur on the important distinction between plaque and patch for the management of early-stage MF. High agreement was reached in 41.7% of questions, since more than 50% of the responders use Olsen's definition of plaque, recommend the distinction between thin/thick plaques, and agree on performing a biopsy on the most infiltrated/indurated lesion. High divergence rates (25%) were reported regarding the possibility of a clinically based distinction between thin and thick plaques and the role of histopathology to plaque definition. ConclusionsThe definition of 'plaque' is commonly perceived as a clinical entity and its integration with histopathological features is generally reserved to specific cases. To date, no consensus is achieved as for the exact definition of thin and thick plaques and current positioning of plaques within the TNMB system is considered clinically inadequate. Prospective studies evaluating the role of histopathological parameters and other biomarkers, as well as promising diagnostic tools, such as US/RM imaging and high-throughput blood sequencing, are much needed to fully integrate current clinical definitions with more objective parameters.
- Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study(2021) QUAGLINO, P.; PRINCE, H. M.; COWAN, R.; VERMEER, M.; PAPADAVID, E.; BAGOT, M.; SERVITJIE, O.; BERTI, E.; GUENOVA, E.; STADLER, R.; QUERFELD, C.; BUSSCHOTS, A. M.; HODAK, E.; PATSATSI, A.; SANCHES, J.; MAULE, M.; YOO, J.; KEVIN, M.; FAVA, P.; RIBERO, S.; ZOCCHI, L.; RUBATTO, M.; FIERRO, M. T.; WEHKAMP, U.; MARSHALKO, M.; MITTELDORF, C.; AKILOV, O.; ORTIZ-ROMERO, P.; ESTRACH, T.; VAKEVA, L.; ENZ, P. A.; WOBSER, M.; BAYNE, M.; JONAK, C.; RUBETA, M.; FORBES, A.; BATES, A.; BATTISTELLA, M.; AMEL-KASHIPAZ, R.; VYDIANATH, B.; COMBALIA, A.; GEORGIOU, E.; HAUBEN, E.; HONG, E. K.; JOST, M.; KNOBLER, R.; AMITAY-LAISH, I.; MIYASHIRO, D.; CURY-MARTINS, J.; MARTINEZ, X.; MUNIESA, C.; PRAG-NAVEH, H.; STRATIGOS, A.; NIKOLAOU, V.; QUINT, K.; RAM-WOLFF, C.; RIEGER, K.; STRANZENBACH, R.; SZEPESI, A.; ALBERTI-VIOLETTI, S.; FELICITY, E.; CERRONI, L.; KEMPF, W.; WHITTAKER, S.; WILLEMZE, R.; KIM, Y.; SCARISBRICK, J. J.Background The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). Objectives To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. Methods In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. Results The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81 center dot 5%), while a smaller percentage (44 cases, 11 center dot 1%) received systemic therapy. Expectant observation was used in 7 center dot 3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0 center dot 001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0 center dot 001), higher modified Severity Weighted Assessment Tool (> 10, 15%; <= 10, 7%; P = 0 center dot 01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0 center dot 001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3 center dot 07) and FMF (odds ratio 2 center dot 83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0 center dot 027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. Conclusions Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.
- IFN-gamma reshapes monocyte responsiveness in Sezary syndrome(2021) TORREALBA, Marina P.; MANFRERE, Kelly C. G.; YOSHIKAWA, Fabio S. Y.; PEREIRA, Natalli Z.; BRANCO, Anna C. C. C.; TEIXEIRA, Franciane M. E.; MIYASHIRO, Denis R.; MARTINS, Jade C.; DUARTE, Alberto J. S.; SANCHES, Jose A.; SATO, Maria N.
- Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib(2018) SATO-SANO, Marcelo; CURY-MARTINS, Jade; MACARENCO, Ricardo; DOMINGUES, Regina Barros; VASCONCELOS, Roberta; SANCHES, Jose Antonio